189 related articles for article (PubMed ID: 19713988)
61. The Proton Pump Inhibitor Omeprazole Does Not Promote Clostridioides difficile Colonization in a Murine Model.
Tomkovich S; Lesniak NA; Li Y; Bishop L; Fitzgerald MJ; Schloss PD
mSphere; 2019 Nov; 4(6):. PubMed ID: 31748246
[TBL] [Abstract][Full Text] [Related]
62. Pathogenic C difficile is here (and everywhere) to stay.
Warren CA; Guerrant RL
Lancet; 2011 Jan; 377(9759):8-9. PubMed ID: 21084110
[No Abstract] [Full Text] [Related]
63. Comorbidities, Exposure to Medications, and the Risk of Community-Acquired Clostridium difficile Infection: a systematic review and meta-analysis.
Furuya-Kanamori L; Stone JC; Clark J; McKenzie SJ; Yakob L; Paterson DL; Riley TV; Doi SA; Clements AC
Infect Control Hosp Epidemiol; 2015 Feb; 36(2):132-41. PubMed ID: 25632995
[TBL] [Abstract][Full Text] [Related]
64. Clostridium difficile colitis: wash your hands before stopping the proton pump inhibitor.
Metz DC
Am J Gastroenterol; 2008 Sep; 103(9):2314-6. PubMed ID: 18924259
[TBL] [Abstract][Full Text] [Related]
65. Regional differences in Clostridium difficile infections in relation to fluoroquinolone and proton pump inhibitor use, Finland, 2008-2011.
Kanerva M; Ollgren J; Voipio T; Mentula S; Lyytikäinen O
Infect Dis (Lond); 2015 Aug; 47(8):530-5. PubMed ID: 25832317
[TBL] [Abstract][Full Text] [Related]
66. Risk factors associated with Clostridium difficile infection in adult oncology patients.
Rodríguez Garzotto A; Mérida García A; Muñoz Unceta N; Galera Lopez MM; Orellana-Miguel MÁ; Díaz-García CV; Cortijo-Cascajares S; Cortes-Funes H; Agulló-Ortuño MT
Support Care Cancer; 2015 Jun; 23(6):1569-77. PubMed ID: 25410088
[TBL] [Abstract][Full Text] [Related]
67. Editorial: Clostridium difficile infection: Yet another predictor of poor outcome in cirrhosis.
Garcia-Tsao G; Surawicz CM
Am J Gastroenterol; 2010 Jan; 105(1):114-6. PubMed ID: 20054307
[TBL] [Abstract][Full Text] [Related]
68. Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low-endemicity, non-outbreak hospital setting.
Dalton BR; Lye-Maccannell T; Henderson EA; Maccannell DR; Louie TJ
Aliment Pharmacol Ther; 2009 Mar; 29(6):626-34. PubMed ID: 19183143
[TBL] [Abstract][Full Text] [Related]
69. Pharmacology of proton pump inhibitors.
Shin JM; Sachs G
Curr Gastroenterol Rep; 2008 Dec; 10(6):528-34. PubMed ID: 19006606
[TBL] [Abstract][Full Text] [Related]
70. Effects of proton pump inhibitor use on risk of Clostridium difficile infection: a hospital cohort study.
Park YH; Seong JM; Cho S; Han HW; Kim JY; An SH; Gwak HS
J Gastroenterol; 2019 Dec; 54(12):1052-1060. PubMed ID: 31187275
[TBL] [Abstract][Full Text] [Related]
71. Acid Suppression Medications During Hospitalization as a Risk Factor for Recurrence of Clostridioides difficile Infection: Systematic Review and Meta-analysis.
Mehta P; Nahass RG; Brunetti L
Clin Infect Dis; 2021 Jul; 73(1):e62-e68. PubMed ID: 32386313
[TBL] [Abstract][Full Text] [Related]
72.
Alalawi M; Aljahdali S; Alharbi B; Fagih L; Fatani R; Aljuhani O
Ann Saudi Med; 2020; 40(4):305-309. PubMed ID: 32757991
[TBL] [Abstract][Full Text] [Related]
73. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected].
Heidelbaugh JJ; Goldberg KL; Inadomi JM
Am J Gastroenterol; 2009 Mar; 104 Suppl 2():S27-32. PubMed ID: 19262544
[TBL] [Abstract][Full Text] [Related]
74. Clostridium difficile infection: an undeniably common problem among hematopoietic transplant recipients.
Zacharioudakis IM; Zervou FN; Ziakas PD; Mylonakis E
Int J Hematol; 2014 Nov; 100(5):514-5. PubMed ID: 25139684
[No Abstract] [Full Text] [Related]
75. Safety of the long-term use of proton pump inhibitors.
Thomson AB; Sauve MD; Kassam N; Kamitakahara H
World J Gastroenterol; 2010 May; 16(19):2323-30. PubMed ID: 20480516
[TBL] [Abstract][Full Text] [Related]
76. Proton pump inhibitor therapy and potential long-term harm.
Corleto VD; Festa S; Di Giulio E; Annibale B
Curr Opin Endocrinol Diabetes Obes; 2014 Feb; 21(1):3-8. PubMed ID: 24310148
[TBL] [Abstract][Full Text] [Related]
77. Risk of Clostridium difficile-associated disease among patients receiving proton-pump inhibitors in a Quebec medical intensive care unit.
Beaulieu M; Williamson D; Pichette G; Lachaine J
Infect Control Hosp Epidemiol; 2007 Nov; 28(11):1305-7. PubMed ID: 17926283
[TBL] [Abstract][Full Text] [Related]
78. Proton pump inhibitors and risk for recurrent Clostridium difficile infection.
Linsky A; Gupta K; Lawler EV; Fonda JR; Hermos JA
Arch Intern Med; 2010 May; 170(9):772-8. PubMed ID: 20458084
[TBL] [Abstract][Full Text] [Related]
79. Proton pump inhibitors: the good, the bad, and the unwanted.
Chubineh S; Birk J
South Med J; 2012 Nov; 105(11):613-8. PubMed ID: 23128806
[TBL] [Abstract][Full Text] [Related]
80. A Comprehensive Assessment Across the Healthcare Continuum: Risk of Hospital-Associated Clostridium difficile Infection Due to Outpatient and Inpatient Antibiotic Exposure.
Tartof SY; Rieg GK; Wei R; Tseng HF; Jacobsen SJ; Yu KC
Infect Control Hosp Epidemiol; 2015 Dec; 36(12):1409-16. PubMed ID: 26387888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
